A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib -resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies.

Trial Profile

A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib -resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hypereosinophilic syndrome; Systemic mastocytosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Aug 2012 Planned number of patients changed from 907 to 965 as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Planned end date changed from 1 May 2014 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top